Evaluating the Effects of Ocrelizumab on the Circulating Metabolome in Multiple Sclerosis (MS)
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
Most Recent Events
- 11 Dec 2023 Status changed from active, no longer recruiting to completed.
- 22 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.
- 09 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Jun 2023.